Why the study?
Does laboratory monitoring of antiplatelet therapy improve clinical outcomes in patients with acute coronary syndrome?
Does laboratory monitoring of antiplatelet therapy improve clinical outcomes in patients with acute coronary syndrome?
Routine laboratory monitoring of antiplatelet therapy may help identify patients with insufficient response to clopidogrel, potentially reducing the risk of thrombotic events.
Answers are grounded in this paper and cite their sources.
Insufficient evidence for routine antiplatelet monitoring in ACS; leaves open whether platelet function testing improves outcomes.
Dual antiplatelet therapy forms currently the basis in acute coronary syndrome pharmacological treatment. However, there is a wide variability in antiplatelet response to clopidogrel, which may lead to antiplatelet therapy insufficient efficacy and subsequent risk of thrombotic events. Laboratory monitoring of antiplatelet therapy may help to identify patients with insufficient antiplatelet response. We discuss the benefits of routine monitoring of antiplatelet therapy in clinical practice.
No takes yet. Share an insight, caveat, or question.
Matej Samos Marian Fedor (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: